Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McDevitt

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|February 5, 2020
A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica NanoparticlesAleksandra M Urbanska, Raya Khanin, Simone Alidori, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 5, 2025
<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast CancerSara S Rinne, Daniela Burnes Vargas, Shin Seo, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistryT K Nikula, M R McDevitt, R D Finn, et al.
Molecular Cancer Research : MCR|January 6, 2023
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy ResponseClaire M Storey, Mohamed Altai, Mesude Bicak, et al.
Nature Communications|July 30, 2016
Deconvoluting hepatic processing of carbon nanotubesSimone Alidori, Robert L Bowman, Dmitry Yarilin, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 14, 2020
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapyMesude Bicak, Katharina Lückerath, Teja Kalidindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Cancer Biotherapy & Radiopharmaceuticals|February 5, 2020
A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica NanoparticlesAleksandra M Urbanska, Raya Khanin, Simone Alidori, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 5, 2025
<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast CancerSara S Rinne, Daniela Burnes Vargas, Shin Seo, et al.
Cancer Research|November 21, 2000
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancerM R McDevitt, E Barendswaard, D Ma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistryT K Nikula, M R McDevitt, R D Finn, et al.
Molecular Cancer Research : MCR|January 6, 2023
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy ResponseClaire M Storey, Mohamed Altai, Mesude Bicak, et al.
Nature Communications|July 30, 2016
Deconvoluting hepatic processing of carbon nanotubesSimone Alidori, Robert L Bowman, Dmitry Yarilin, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 14, 2020
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapyMesude Bicak, Katharina Lückerath, Teja Kalidindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Pageof 12